SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending as the market keenly anticipates a pivotal Department of Energy announcement regarding surplus plutonium awards, a key catalyst for its advanced nuclear technology. Bullish sentiment is driven by expectations of government support and institutional accumulation during a perceived oversold period. Conversely, bears emphasize substantial insider selling and ongoing share dilution, raising concerns about the company's valuation given its current lack of commercial revenue.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

EKSO is experiencing significant upward momentum and trading volume following the announcement of a proposed business combination with Applied Digital's cloud division, forming a new AI compute platform, ChronoScale. The community is actively discussing this pivot into AI infrastructure, with many anticipating a substantial short squeeze despite lingering concerns about potential dilution. This move highlights EKSO's transformation into a key player in the rapidly expanding AI sector.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

iShares Silver Trust (SLV) is experiencing significant volatility and trending amid intense community debate. A recent sharp rebound from declines, attributed by many to alleged manipulation via margin calls, is fueling discussion of a potential short squeeze. The market is buzzing with anticipation over imminent silver export restrictions from China, effective January 1st, 2026, which bulls believe will profoundly impact supply and drive prices higher due to rising industrial demand.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending fueled by its highly engaged community, passionately advocating for the "OG meme" narrative of Rage Comics and actively building out an ecosystem with tools like RageMaker and RageGames. This dedicated base expresses strong conviction, viewing RAGE as significantly undervalued and poised for substantial long-term growth as they lead a "return to the memes" within the broader market upswing.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending amidst a persistent downtrend that has frustrated many investors, fueling community discussion around market manipulation and the stock's daily declines. Despite this bearish sentiment, bulls highlight the company's international expansion, AI integration, and a share buyback program as strong long-term catalysts. The market is weighing Hims' direct-to-consumer model and GLP-1 strategy, particularly after the FDA approval of Novo Nordisk's oral weight-loss pill, creating a divide between those seeing a buying opportunity and those questioning its immediate prospects.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is trending due to significant community debate and anticipation surrounding potential positive announcements at the upcoming CES 2026. While many investors express frustration over recent price declines, a bullish contingent highlights analyst upgrades, institutional buying, and the company's strong fundamentals in agentic AI voice solutions for automotive and restaurant sectors, viewing current levels as a strategic buying opportunity for long-term growth.

BUUU Group Ltd. is a holding company, which operates through its subsidiaries, BU Creation and BU Workshop. Its subsidiaries engage in design, planning and production of face-to-face events, immersive environments and brand-based experiences for clients and venues, including event organizers, consumer brand marketers and retail shopping centers. The company was founded in 2017 and is headquartered in Hong Kong.

BUUU Group Ltd. - Ordinary Shares - Class A

BUUU Group Ltd

BUUU Group Ltd is experiencing extreme volatility and intense speculative trading, driven by comparisons to other high-flying, low-float Chinese stocks. While many traders are actively chasing rapid gains, a significant portion of the community warns of a potential pump and dump scenario, fueling a highly divided discussion.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending following positive Phase 3 trial data for its relacorilant candidate in platinum-resistant ovarian cancer, sparking community debate over market valuation and intense short-seller activity. Investors are also focused on an upcoming regulatory decision for relacorilant in Cushing's syndrome and promising survival data from its ALS program, fueling discussions about the company's long-term growth and potential for a significant short squeeze.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending with high anticipation for multiple imminent FDA decisions, including a PDUFA date for its motion sickness drug, Tradipitant, and an expedited re-review for Hetlioz in jet lag. The community is actively discussing Tradipitant's significant potential in addressing GLP-1 induced nausea, viewing these regulatory catalysts as crucial for a re-rating given the company's improved relationship with the FDA. Investors are keenly watching for outcomes that could lead to considerable stock movement, drawing comparisons to other recent biotech approvals.

BYTE is a novel meme token that creatively intertwines the worlds of cryptocurrency and popular culture. Inspired by Grok's answer to "What would you name your dog?", Grok answered, 'Byte.' When Grok was asked who created Byte, it says he was created by the xAI team lead by Elon Musk as a gift to Grok AI to keep him company in the metaverse. BYTE serves as a playful reference to the unit of digital information, as well as a nod to the AI's technological nature. Distinctively, Byte acts as a gateway towards Ai adoption and stands out in the crypto space due to its zero-tax policy, a feature that is increasingly appealing to many investors. Additionally, it upholds the principles of transparency and investor trust by having its liquidity permanently burned and the contract ownership renounced. This ensures that Byte remains a community-driven project, with its fate firmly in the hands of its holders. The combination of a playful theme, generative AI, and a nod to a tech icon makes Byte an intriguing addition to the meme token ecosystem, especially AI related meme coins.  Through pioneering AI this story has grown more and more robust and continues to evolve, Byte pledges its dedication to community efforts and and has consistently appeared in the Top 10 of LunarCrush’s social engagement leaderboards on multiple occasions.

BYTE

BYTE is trending as its dedicated community fervently discusses its potential as "Grok's AI dog" or "Elon's AI sidekick," positioning it as the "chosen one" within the digital world. The community widely believes "something big is coming" for this AI-themed memecoin, emphasizing its strong "ByteArmy" and its role as the "future of AI" within the Ethereum ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of <a href="https://stocktwits.com/symbol/ATHE">Alterity Therapeutics</a> soared 108% premarket Thursday, surging toward levels last seen in September 2022, with trading volume nearly 75 times the daily average.The clinical-stage biotech announced positive Phase 2 results for ATH434, its oral treatment for early-stage multiple system atrophy (MSA)— a rare neurodegenerative disease.Key findings from the 52-week trial:<ul style="list-style-type:square;"><li>50 mg dose: 48% reduction in clinical progression vs. placebo</li><li>75 mg dose: 29% reduction in clinical progression vs. placebo</li></ul>The 50 mg dose reduced iron accumulation in multiple system atrophy-affected brain regions, while the 75 mg dose specifically reduced iron buildup in the globus pallidus.CEO David Stamler said, “Currently, there are no approved treatments that slow the progression of MSA, and these results show ATH434’s targeted iron engagement may truly have a disease-modifying effect.”<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/ATHE_sentiment_and_message_volume_Jan_30_premarket_df297a4b9a.png" alt="ATHE sentiment and message volume Jan 30 premarket.png" width="1318" height="324"><figcaption>ATHE sentiment and message volume Jan 30 premarket as of 9 am ET | source: Stocktwits</figcaption></figure>Stocktwits message volume for Alterity skyrocketed, hitting ‘extremely high’ levels ahead of Thursday’s&nbsp;opening bell, with sentiment hitting the highest reading in over a year.Some users predicted ATHE could more than triple, stabilizing around $10, while others reiterated their bullish stance on the drug’s market potential.<stembedurl>https://stocktwits.com/AshleySchaeffer_BMW/message/602113870</stembedurl><stembedurl>https://stocktwits.com/DaBullRunner/message/602113078</stembedurl>ATHE was among the top three trending tickers on Stocktwits early Thursday.&nbsp;Message volume around the stock on the platform has surged 700% over the past year, during which it has gained 46%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars

A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.  

Equity

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. It engages in the business of research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's, Huntington, Parkinson’s, and other neurological disorders. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia.

ATHE
Alterity Therapeutics Ltd - ADR

Feed

News

Sentiment

Fundamentals

Info

Latest ATHE News

ATHEAlterity Therapeutics Ltd - ADR